Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tourmaline Bio, Inc. - Common Stock
(NQ:
TRML
)
28.76
+1.10 (+3.98%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tourmaline Bio, Inc. - Common Stock
< Previous
1
2
Next >
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 07, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
October 31, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
October 15, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023
March 19, 2024
Tourmaline Bio just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
October 11, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
October 08, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
September 03, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q2 2024
August 08, 2024
TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
August 02, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
June 27, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
May 23, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
May 16, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024
May 13, 2024
TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 13, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
April 02, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 21, 2024
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
March 21, 2024
Via
Benzinga
Dow Jumps 200 Points; US Weekly Jobless Claims Fall
March 21, 2024
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.52% to 39,718.37 while the NASDAQ rose...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
March 21, 2024
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 21, 2024
Via
Benzinga
Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 21, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 19, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 29, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
January 25, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 24, 2024
Via
Benzinga
Tourmaline Bio Announces Proposed Public Offering of Common Stock
January 24, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
January 08, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
January 03, 2024
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.
Via
MarketBeat
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.